YKL-40: may be use as a new inflammatory biomarker in obstructive sleep apnea syndrome?
Giriş: YKL-40 [chitinase-3 like-1 (CHI3L1)], inflamasyon, endotel disfonksiyonu, remodellingde rol oynayan ve inflamasyon için noninvaziv prognostik biyobelirteç olarak kabul edilen bir glikoproteindir. Bu çalışmada, obstrüktif uyku apne sendromlu (OSAS) hastalarda YKL-40ın bir inflammatory biyobelirteç olarak kullanılabilirliğini göstermeyi amaçladık. Hastalar ve Metod: Çalışmaya iki grup OSASlı hasta [Grup I: Hafif-Orta OSAS; n: 43, apnea-hypopnea indeksi; AHI, /saat: 18 (7.1- 28.2), Grup II: Ağır OSAS; n: 25, AHI: 41.6 (33.9-86.9)] ve sağlıklı kontrol grubu [n: 25, AHI: 3.6 (0.4-5) ] alındı. Polisomnografi sonrası OSAS'lı hastalar ve kontrol grubunun serum YKL-40 düzeyleri incelendi. Ayrıca OSASlı hasta gruplarında serum YKL-40 düzeyinin yaş, vücut kitle indeksi ve polisomnografik parametreler ile olan ilişkisi araştırıldı. Bulgular: Ortalama serum YKL-40 düzeyi hafif-orta OSASlı hastalarda 20.30 ng/mL (8.01-73 ng/mL), ağır OSASlı hastalarda 22.58 ng/mL (9.17-99 ng/mL) ve kontrol grubunda 18 ng/mL (7.36-88 ng/mL) olarak bulundu (p= 0.01). Hafif-orta OSASda AHI ile (p< 0.05), ağır OSASta ise yaş, total hipopne süresi (dakika) ile serum YKL-40 düzeyi arasında (p< 0.05) korelasyon olduğu görüldü. Ancak diğer değişkenler ile serum YKL-40 düzeyi arasında ilişki saptanmadı (p> 0.05). Sonuç: Bu çalışma sonucunda OSASın ağırlığı ile serum YKL-40 düzeyinin birlikte arttığını saptadık. Bu bulgular YKL-40ın OSASlı hastalarda inflamasyon için kullanılabilir bir biyobelirteç olabileceğini düşündürmektedir.
YKL-40: Obstrüktif uyku apne sendromunda yeni bir inflamatuvar biyobelirteç olarak kullanılabilir mi?
Introduction: YKL-40 [chitinase-3 like-1 (CHI3L1)] is a glycoprotein, has been implicated in inflammation, endothelial dysfunction, tissue remodelling and it is accepted as a noninvasive prognostic biomarker for inflammation. In this study, we aimed to underline usability of serum YKL-40 as an inflammatory biomarker in patients with obstructive sleep apnea syndrome (OSAS). Patients and Methods: Two groups OSAS patients [Group I: Mild-moderate OSAS, n:43; median apnea-hypopnea index: AHI, /hour:18], Group II: Severe OSAS, n: 25; AHI:41.6] and healthy control group [n:25, AHI: 3.6] were included in the study. Serum YKL-40 level was tested in serum samples taken after polysomnography in OSAS patients and control group. In addition, the association of serum YKL-40 level with age, body mass index and polysomnografic parameters were analyzed in the OSAS patient groups. Results: Median serum YKL-40 level was 20.30 ng/mL (range 8.01-73 ng/mL) in mild-moderate OSAS patients, and 22.58 ng/mL (9.17-99 ng/mL in severe OSAS patients, 18 ng/mL (range 7.36-88 ng/mL) in control group (p< 0.05). Serum YKL-40 level was found to be correlated with AHI in patient with mild-moderate OSAS patients (p< 0.05) and serum YKL-40 level was found to be correlated with age, total hypopnea time (minutes) in severe OSAS patients (p< 0.05). There was no relationship serum YKL-40 level with other studied variables (p> 0.05). Conclusion: At the end of this study, we found that serum YKL-40 level increase with severity of OSAS. The findings suggest that YKL- 40 may be a useful biomarker for inflammation in patients with OSAS.
___
- 1. Partinen M, Jamieson A, Guilleminault C. Long-term outcome for obstruktive sleep apnea syndrome patients: mortality. Chest 1988;94:1200-4.
- 2. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89.
- 3. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5.
- 4. Demir A, Ursavaş A, Tana Aslan A, Gülbay B, Çiftçi B, Çuhadaroğlu Ç, et al. Obstrüktif uyku apne sendromu tanı ve tedavi uzlaşı raporu. Türk Toraks Derneği 2012;1-73.
- 5. Thropy MJ, Broughton RJ, Cohn MA, et al. American Academy of Sleep Medicine. International classification of sleep disorders. Diagnostic and coding manual (ICSD-2). 2nd ed. American Academy of Sleep Medicine: Westchester, IL, 2005.
- 6. Iber C, Ancoli-Israel S, Chesson A, Quan SF, American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. American Academy of Sleep Medicine: Westchester, IL, 2007.
- 7. Meoli AL, Casey KR, Clark RW, Coleman JA Jr, Fayle RW, Troell RJ, et al. Hypopnea in sleep-disordered breathing in adults. Sleep 2001;24:469-70.
- 8. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89.
- 9. Imeri L, Opp MR. How (and why) the immune system makes us sleep. Nat Rev Neurosci 2009;10:199-210.
- 10. Mehra R, Storfer-Isser A, Kirchner HL, Johnson N, Jenny N, Tracy RP, et al. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med 2006;166:1725-31.
- 11. Arter JL, Chi DS, Girish M, Fitzgerald SM, Guha B, Krishnaswamy G, et al. Obstructive sleep apnea, inflammation and cardiopulmonary disease. Front Biosci 2004;1:2892- 900.
- 12. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
- 13. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-10.
- 14. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006;281:21082-95.
- 15. Funkhouser JD, Aronson NN Jr. Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family. BMC Evol Biol 2007;7:96.
- 16. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172-209.
- 17. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, et al. Role of breast regression protein 39 (BRP-39)/ chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206:1149-66.
- 18. Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol 2012;22:530-46.
- 19. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010;7:34.
- 20. Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, et al. Association between YKL-40 and adult primary astrocytoma. Cancer 2010;116:2688-97.
- 21. Bonneh-Barkay D, Zagadailov P, Zou H, Niyonkuru C, Figley M, Starkey A, et al. YKL-40 expression in traumatic brain injury: an initial analysis. J Neurotrauma 2010;27:1215-23.
- 22. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010;68:903-12.
- 23. Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath 2008;12:161-8.
- 24. Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, et al. Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med 2012;185:715-22.
- 25. Francescone RA, Scully S, Falbish M, Taylor SL, Oh D, Moral L, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011;286:15332-43.
- 26. Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, et al. YKL-40 in asthmatic patients and its correlations with exacerbations, eosinophils and immunglobulin E. Eur Respir J 2010;35:757- 60.
- 27. Røndjberg AK, Omerovic E, Vestergaard H. YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovasc Diabetol 2011;10:54.
- 28. Volck B, Johansen JS, Staltenberg M, Garbarsch C, Price PA, Ostergaard M, et al. Studies on ykl-40 in knee joints of patients with rheumatoid arthiritis and osteoarthiritis. Involvement of ykl-40 in the joint pathology. Osteoarthiritis Cartilage 2001;9:203-14.
- 29. Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung carcinoma. Cancer 2010;116:4114-21.
- 30. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-20.
- 31. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am. J Pathol 2008;173:130-43.
- 32. Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M, et al. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett 2008;582:3193-200.
- 33. Recklies AD, Ling H, White C, Bernier SM. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 2005;280:41213-21.
- 34. Bonneh-Barkay D, Zagadailov P, Zou H, Niyonkuru C, Figley M, Starkey A, et al. YKL-40 expression in traumatic brain injury: an initial analysis. J Neurotrauma 2010;27:1215-23.
- 35. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004;291:2013-6.
- 36. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129-1134.